11/20/2026 | Press release | Distributed by Public on 11/20/2026 15:55
Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis is based on, and should be read in conjunction with, the audited financial statements and the notes thereto for the two years ended December 31, 2025, included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 15, 2026. This discussion contains forward-looking statements. These statements are often identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue," and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
Overview
We do not currently have sufficient capital resources to fund operations. To stay in business and to continue the development of our products, we will need to raise additional capital through public or private sales of our securities, debt financing or short-term bank loans, or a combination of the foregoing. We believe that if we can raise $3,700,000, we will have sufficient working capital to develop our business over the next approximately fifteen (15) months. At funding raised that is significantly less than $3,700,000, we can likely continue to develop our business over the same 15-month period, but funding at that level will delay the development of our technology and business.
Bioxytran, Inc. is headquartered in Needham, Massachusetts. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for stroke. BXT-25 will be designed to be an injectable anti-necrosis drug specifically designed to treat a person immediately after that person suffers an ischemic stroke. The drug is designed to be injected intravenously to travel to the lungs to pick up oxygen molecules to carry to the brain. Like a red blood cell, the drug will cross the blood brain barrier, which is a protective semi-permeable membrane allowing some material to cross but preventing others from crossing. BXT-25 will be designed to diffuse oxygen into the brain tissues. We expect the BXT-25 molecule to be 5,000 times smaller than a red blood cell.
Provided that the Company obtain adequate funding, the following future milestones are anticipated:
| ● | On December 2, 2022, India's Central Drugs Standard Control Organisation (CDSCO) issued an IND with permission to conduct: "A Phase 1b/2a Randomized, Blinded, placebo-controlled Study in Participants with Mild to Moderate COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Orally Administered ProLectin-M". The recruitment for the trial was completed on May 1, 2026. The results from the trial report, including issuance to the CDSCO, is scheduled for publication within the following 90 days. Provided positive trial results, the Company will schedule a Phase 3 clinical trial with the CDSCO. | |
| ● | On August 21, 2023, the Company's IND #153742 under the title "PROTECT: ProLectin-M, a nucleocapsid TErminal GaleCTin antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded Clinical Trial to Evaluate the Efficacy and Safety in Non-Hospitalized Adult Participants with COVID-19" was approved by the FDA, the trial is expected to start in the first quarter of 2027. | |
| ● | On January 27, 2023, an additional IND with the CDSCO was issued for ProLectin-I for an "IV treatment of SARS-CoV-2 in hospitalized patients with moderate Covid-19 infections and for Long Covid", and for ProLectin-F for "treatment of lung-fibrosis as a result of use of ventilator", the trial is expected to start in the first quarter of 2027. | |
| ● | On April 19, 2023, the Company announced that its Acelluar Oxygen Carrier ("AOC") BXT-25 had been successfully tested in animals. The initial results are very encouraging because they show the non-toxicity of the experimental drug, along with the corresponding full recovery in Swiss Albino mice, in an experiment carried out in a joint venture with NDPD Pharma, Inc. As a next step, the Company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats. |
The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. The Company currently has one convertible loan outstanding at a total face value of $805,000 with an accrued interest of $386,333 and a linked derivative debt of $1,368,347. The remaining debt amounts to $3,896,343 (whereof $2,912,896 is owed to affiliates with an accrued interest of $92,761). As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit of $25,011,000 as at September 30, 2026. The accumulated deficit as at December 31, 2025, was $21,044,246.
The future of the Company is dependent upon its ability to obtain financing to develop its new business opportunities and support the cost of the drug development including clinical trials and any regulatory submission to the FDA.
Management plans to seek additional capital through private placements and public offerings of its Common Stock. There can be no assurance that the Company will be successful in accomplishing its objectives. Without such additional capital or the establishment of strategic relationships with established pharmaceutical companies, the Company may be required to cease operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations.
RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026, AND 2025
We are a clinical stage company. Historically, Bioxytran was engaged in formation, fund raising and identifying and consulting with the scientific community regarding the development, formulation and testing of its products. We are actively engaged in research and development activities through our Subsidiary, Pharmalectin, Inc., developing the ProLectin-Rx.
OPERATING EXPENSES
| Three months ended | Nine months ended | |||||||||||||||
| Research and development | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||
| Process development | $ | - | $ | - | $ | 5,100 | $ | 100,000 | ||||||||
| Product development | 38,710 | - | 75,595 | (500 | ) | |||||||||||
| Clinical trials | - | - | - | 352,500 | ||||||||||||
| Regulatory | (183,045 | ) | - | 243,928 | - | |||||||||||
| Project management | 6,000 | - | 18,000 | - | ||||||||||||
| Total research and development | $ | (138,335 | ) | $ | - | $ | 342,623 | $ | 452,000 | |||||||
| ● | The three months ended September 30, 2026, resulted in a negative $(138,335) R&D expense after 183,045 in credit notes were received. During the three months ended September 30, 2025, the Company did not record any R&D expenses. | |
| ● | During the nine months ended September 30, 2026, the Company recorded $342,623 in R&D expenses. During the nine months ended September 30, 2025, the Company recorded $ 452,000 in R&D expenses. |
| Three months ended | Nine months ended | |||||||||||||||
| General and Administrative | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||
| Payroll and related expenses | $ | 262,567 | $ | 388,255 | $ | 787,701 | $ | 389,539 | ||||||||
| Costs for legal, accounting and other professional services | 40,249 | 20,831 | 179,625 | 106,020 | ||||||||||||
| Costs for professional services affiliates | - | - | 5,000 | 5,000 | ||||||||||||
| Promotional expenses | - | - | 38,950 | 21,000 | ||||||||||||
| Miscellaneous expenses | 27,169 | 43,178 | 127,573 | 148,862 | ||||||||||||
| Compensation expense | 10,882 | (4,383 | ) | 30,112 | 36,884 | |||||||||||
| Compensation expense affiliates | - | 48,124 | 1,278,600 | 75,919 | ||||||||||||
| Total general and administrative | $ | 340,866 | $ | 496,005 | $ | 2,447,561 | $ | 783,224 | ||||||||
| ● | Payroll and related expenses were $262,567 for the three months ended September 30, 2026, and $787,701 for the nine months ended September 30, 2026. For the same periods in 2025, the amount was $388,255 and $389,539, respectively. This was a result from the Company's Officers forfeiting payroll of $941,890, whereof $362,931 and $727,110 over the same periods, while $214,780 was accrued in 2024. (See note 7 for more details). | |
| ● | The Costs for legal, accounting and other professional services for the three and nine months ended September 30, 2026, were $40,249 and $179,625 respectively, as compared to $20,831 and $106,020 for the three and nine months ended September 30, 2025. The increased costs were a result of a litigation with a former officer. These costs include Stock issued as compensation for professional services for a total of $52,259 and $5,244 for the nine and three months ended September 30, 2026. | |
| ● | Promotional expenses for the three and nine months ended September 30, 2026, were $0 and $38,950 respectively, as compared to $0 and $21,000 for the three and nine months ended September 30, 2025. | |
| ● | Miscellaneous G&A expenses during the three and nine months ended September 30, 2026, was $27,169 and $127,573, respectively. During the three and nine months ended September 30, 2025, was $43,178 and $148,862. | |
| ● | Stock-based compensation amounted to $10,882 (of which $0 was to affiliates) for the three months ended September 30, 2026. The stock-based compensation for the three months ended September 30, 2025, was $43,741 (of which $48,124 was to affiliates). Stock-based compensation amounted to $1,308,712 (of which $1,278,600 was to affiliates) for the nine months ended September 30, 2026. Stock-based compensation amounted to $112,802 (of which $75,919 was to affiliates) for the nine months ended September 30, 2025. The significant fluctuation in net profit (loss) can be attributed a one-time bonus awarded to the Company's CEO of $1,278,600 as a performance grant in recognition of his role in executing the Company's first commercial distribution agreement and advancing capital funding initiatives. |
| Three months ended | Nine months ended | |||||||||||||||
| Other expenses | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||
| Change in fair value ("FV") of derivative | $ | 998,617 | $ | (264,796 | ) | $ | 964,994 | $ | 232,554 | |||||||
| Interest expense | 36,522 | 36,522 | 108,377 | 97,791 | ||||||||||||
| Interest expense affiliates | 36,025 | 10,759 | 91,370 | 26,757 | ||||||||||||
| Amortization of IP | 4,141 | 4,236 | 11,829 | 8,596 | ||||||||||||
| Total other (income) expenses | $ | 1,075,305 | $ | (213,279 | ) | $ | 1,176,570 | $ | 365,698 | |||||||
| ● | During the three months ended September 30, 2026, the interest expense was $72,547 (of which $36,025 was to affiliates), $4,141 was amortized from the Company's IP and the derivative liability was increased by $998,617. During the three months ended September 30, 2025, the interest expense was $47,281 (of which $10,759 was to affiliates), $4,236 was amortized from the Company's IP and the derivative liability was reduced by $264,796. | |
| ● | During the nine months ended September 30, 2026, the interest expense was $199,747 (of which $91,370 was to affiliates), $11,829 was amortized from the Company's IP and the derivative liability was increased by $964,994. During the nine months ended September 30, 2025, the interest expense was $124,548 (of which $26,757 was to affiliates), the Company amortized $8,596 from the Company's IP while the derivative liability increased by $232,554. |
| Three months ended | Nine months ended | |||||||||||||||
| Net Loss | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||
| Net profit (loss) attributable to Bioxytran | $ | (1,277,836 | ) | $ | (282,726 | ) | $ | (3,966,754 | ) | $ | (1,600,922 | ) | ||||
| Loss per Common share, basic and diluted | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
| Weighted average number of Common shares outstanding, basic | 114,695,219 | 88,992,242 | 113,869,289 | 88,942,337 | ||||||||||||
| ● | In the three months ended September 30, 2026, the Company generated a net loss of $1,277,836. In comparison, for the three months ended September 30, 2025, the Company generated a net loss of $282,726. The Company generated a net loss for the nine months ended September 30, 2026, of $3,966,754. In comparison, for the nine months ended September 30, 2025, the Company generated a net loss of $1,600,922. The significant fluctuation in net profit (loss) can be attributed a one-time bonus awarded to the Company's CEO of $1,278,600 as a performance grant in recognition of his role in executing the Company's first commercial distribution agreement and advancing capital funding initiatives. |
LIQUIDITY AND CAPITAL RESOURCES
| Cash and Cash Equivalents | September 30, 2026 | December 31, 2025 | ||||||
| Cash | $ | 74,369 | $ | 509,914 | ||||
| Pre-payment | - | 3,551 | ||||||
| Total current assets | $ | 74,369 | $ | 513,465 | ||||
| ● | As of September 30, 2026, our current assets consisted of $74,369 in cash. At December 31, 2025 we had $509,914 in cash and $3,551 in pre-payments. |
| Current Liabilities | September 30, 2026 | December 31, 2025 | ||||||
| Accounts payable and accrued expenses | $ | 1,137,582 | $ | 824,278 | ||||
| Accounts payable affiliates | 1,289,453 | 673,317 | ||||||
| Un-issued shares liability | 89,437 | 16,272 | ||||||
| Un-issued shares liability affiliates | 1,360,606 | 82,006 | ||||||
| Loan from affiliates | 355,598 | 395,668 | ||||||
| Other short-term loans | 50,000 | 50,000 | ||||||
| Derivative Liability | 1,368,347 | 403,353 | ||||||
| Convertible notes payable, net of premium and discount | 805,000 | 805,000 | ||||||
| Total current liabilities | $ | 6,456,023 | $ | 3,249,894 | ||||
| ● | At September 30, 2026, we had total liabilities of $6,456,023, which consisted of $2,427,035 in accounts payable and accrued expenses (of which $1,289,453 was payable to related parties), $1,450,043 in un-issued shares (of which $1,360,606 was due to related parties), and $805,000 in one convertible loan coupled with a derivative liability of $1,368,347 and $355,598 in a loan from affiliates and $50,000 in other short-term loans. At December 31, 2025, we had total liabilities of $3,249,894, which consisted of $1,497,595 in accounts payable and accrued expenses (of which $673,317 was payable to related parties), $98,278 in un-issued shares (of which $82,006 was due to related parties), and $805,000 in one convertible loan coupled with a derivative liability of $403,353 and $395,668 in a loan from affiliates and $50,000 in other short-term loans. |
| Net Working Capital and Accumulated Deficit | September 30, 2026 | December 31, 2025 | ||||||
| Net working capital | $ | (6,381,654 | ) | $ | (2,736,429 | ) | ||
| Accumulated deficit | $ | (25,011,000 | ) | $ | (21,044,246 | ) | ||
| ● | At September 30, 2026, the net working capital was negative ($6,381,654) and the accumulated deficit of $25,011,000. Comparatively, on December 31, 2025, we had net working capital of negative ($2,736,429) and the accumulated deficit of $21,044,246. We believe that we must raise not less than $3,700,000 to be able to continue our business operations for the next 15 months. |
CASH-FLOWS
| September 30, 2026 | September 30, 2025 | |||||||
| Net cash used in operating activities | $ | (680,751 | ) | $ | (289,484 | ) | ||
| Net cash used in investing activities | (37,147 | ) | (16,851 | ) | ||||
| Net cash provided by financing activities | 282,353 | 315,680 | ||||||
| Net increase (decrease) in cash | (435,545 | ) | 9,345 | |||||
| Cash, beginning of period | 509,914 | 5,154 | ||||||
| Cash, end of period | $ | 74,369 | $ | 14,499 | ||||
| ● | Net cash used in operating activities was $(680,751) and $(289,484) for the nine months ended September 30, 2026, and 2025, respectively. | |
| ● | Net cash used in investing activities: In the nine months ended September 30, 2026, the Company invested $37,147 in IP filing fees. In the nine months ended September 30, 2025, the amount was $16,851. | |
| ● | Cash flows from financing activities were 282,353 and $315,680 for the nine months ended September 30, 2026, and 2025, respectively. | |
| ● | The available cash was $74,369 and $14,499 in the end of the nine months ended September 30, 2026, and 2025, respectively. |
| Cash Proceeds from Financing Activities | September 30, 2026 | September 30, 2025 | ||||||
| Cash proceeds from financing activities | ||||||||
| Stock transactions | $ | 191,047 | $ | 13,353 | ||||
| Short-term loans | - | 2,000 | ||||||
| warrants issued | 131,376 | |||||||
| Short-term loans from affiliates | (40,070 | ) | 300,327 | |||||
| Net cash provided by financing activities | $ | 282,353 | $ | 315,680 | ||||
| ● | During the nine months ended September 30, 2026, the Company raised a total of $282,353 through private placements consisting of $191,047 in stock and $131,376 in warrants to purchase Common Stock, while repaying $40,070 in an affiliate loan. During the nine months ending September 30, 2025, the Company had raised $13,353, and borrowed $302,327 from its affiliates and as well as a short-term loan of $2,000. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of December 2026. |
Planned Financing Activities
The Company believes it needs to raise approximately $2-3 million in 2026. However, there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.
Commitments
We have no current commitment from our Officers and Directors or any of our shareholders, to supplement our operations or provide us with financing in the future. If we are unable to raise additional capital from conventional sources and/or additional sales of stock in the future, we may be forced to curtail or cease our operations. Even if we are able to continue our operations, the failure to obtain financing could have a substantial adverse effect on our business and financial results. In the future, we may be required to seek additional capital by selling debt or equity securities, selling assets, or otherwise be required to bring cash flows in balance when we approach a condition of cash insufficiency. The sale of additional equity or debt securities, if accomplished, may result in dilution to our then shareholders. We provide no assurance that financing will be available in amounts or on terms acceptable to us, or at all.
Contractual Obligations
Convertible Note
| September 30, 2026 | December 31, 2025 | |||||||
| Interest on notes payable | $ | 386,333 | $ | 277,956 | ||||
| Convertible notes payable | 805,000 | 805,000 | ||||||
| Total | $ | 1,191,333 | $ | 1,082,956 | ||||
| ● | As at September 30, 2026, our contractual obligations include one convertible note with a principal of $805,000, the accrued interest for these notes mounting to $386,333. As at December 31, 2025, there were four convertible notes with a principal of $805,000, the accrued interest for these notes mounting to $277,956. | |
| ● | The Convertible Note, issued on May 3, 2021, carries an interest rate of 10%. The Note has been in default since March 1, 2025, with a default interest of 18%. It is convertible at the lower of (i) a fixed price of $0.08, or (ii) if the market price at the date of conversion is below $0.08, the conversion price will be reduced by 120% of the difference between the conversion price and the market price. |
Employment Agreements
The Company's Executive Officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements.
On October 28, 2022, the Bioxytran Board of Directors unanimously approved the modification of/amendment of paragraph 8 to the Officers' Employment Agreements, referring to termination without cause in case of change of control.
The most substantial changes encompass;
| ● | Compensation of three times the annual salary upon the Termination Date, plus any target bonus earned. | |
| ● | Continued coverage under any health, medical, dental or vision program or policy in which they were eligible to participate at the time of your employment termination for 12 months. | |
| ● | Provide outplacement services through one or more outside firms of their choosing up to an aggregate of $50,000. |
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.
CRITICAL ACCOUNTING POLICIES
In presenting our financial statements in conformity with generally accepted accounting principles, we are required to make estimates and assumptions that affect the amounts reported therein. Several of the estimates and assumptions we are required to make relate to matters that are inherently uncertain as they pertain to future events. However, events that are outside of our control cannot be predicted and, as such, they cannot be contemplated in evaluating such estimates and assumptions. If there is a significant unfavorable change to current conditions, it could result in a material adverse impact to our results of operations, financial position and liquidity. We believe that the estimates and assumptions we used when preparing our financial statements were the most appropriate at that time. Presented below are those accounting policies that we believe require subjective and complex judgments that could potentially affect reported results. However, the majority of our businesses operate in environments where we pay a fee for a service performed, and therefore the results of the majority of our recurring operations are recorded in our financial statements using accounting policies that are not particularly subjective, nor complex.
Stock Based Compensation
The Company has share-based compensation plans under which non-employees, consultants and suppliers may be granted restricted stock, as well as options to purchase shares of Company Common Stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award over the requisite service period.
The Company applies ASC 718 for options, Common Stock and other equity-based grants to its employees and Directors. ASC 718 requires measurement of all employee equity-based payment awards using a fair-value method and recording of such expense in the consolidated financial statements over the requisite service period. The fair value concepts have not changed significantly in ASC 718; however, in adopting this standard, companies must choose among alternative valuation models and amortization assumptions. After assessing alternative valuation models and amortization assumptions, the Company will continue using both the Black-Scholes valuation model and straight-line amortization of compensation expense over the requisite service period for each separately vesting portion of the grant.
Fair Value
Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10") and Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10"), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Warrant Valuation
The Company accounts for warrants issued in connection with financing transactions in accordance with ASC 815 (Derivatives and Hedging) or ASC 505 (Equity), as applicable. Warrants that are freestanding and meet the criteria for equity classification are recorded at fair value on the issuance date and allocated proceeds based on relative fair value when issued with other securities.
For warrants classified as equity, fair value is estimated using the Black-Scholes option-pricing model. Key inputs include the fair value of the underlying Common Stock, exercise price, expected term, risk-free interest rate, expected volatility, and expected dividend yield. Changes in these assumptions could materially affect the estimated fair value. Warrants classified as liabilities are remeasured at each reporting date, with changes in fair value recognized in earnings.
The Company accounts for warrants issued in connection with equity offerings in accordance with ASC 505-10-30-6, allocating proceeds between Common Stock and detachable warrants based on their relative fair values.
Segment Reporting
The Company has not yet begun generating revenue from its planned principal operations and operates a single reportable segment. The chief operating decision maker is the Company's chief executive officer who assesses performance based on total expenses, cash-flows, and progress made in the Company's ongoing development efforts. All of the Company's long-lived assets are located in the United States.
Recent Accounting Pronouncements
Management does not believe that any recent issued, but not yet effective, accounting standards could have any material effect on the financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.